Form 4: Cassava Sciences CEO Richard Barry Granted 600,000 Stock Options

Richard Barry, President & CEO of Cassava Sciences, was granted 600,000 stock options on October 1, 2024, according to a Form 4 filing.

Summary

• Richard Barry, the President & CEO of Cassava Sciences, received 600,000 stock options on October 1, 2024.
• The exercise price of these options is $27.42.
• The options vest in four equal annual installments, with the first 25% vesting on July 15, 2025.
• The options expire on October 1, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard executive compensation disclosure. The grant itself is neither overwhelmingly positive nor negative.

Positives

• The granting of stock options to the CEO can align his interests with those of the shareholders, incentivizing him to increase the company's value.

Risks

• The vesting schedule means the CEO only benefits if he remains with the company and the stock price appreciates over time.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders. The size and vesting schedule of the grant are typical considerations.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options as part of their executive compensation plans.
• The specific number of options and vesting schedules vary based on company size, performance, and industry benchmarks.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the CEO.
• Employees may see it as a sign of confidence in the company's future.

Key Dates